Helus Pharma Inc. Common Stock

Helus Pharma to Participate in the Guggenheim Healthcare Innovation Conference

Helus Pharma CEO Michael Halstead will participate in a fireside chat at the Guggenheim Healthcare Innovation Conference in Boston. The chat will be webcast live on Monday, November 9, 2026 at 3:00 p.m. EDT, with a replay on the company's investor relations site. The release contains no new results; Helus's lead asset HLP003 remains in Phase 3 for adjunctive major depressive disorder with FDA Breakthrough Therapy Designation.

•6d ago

Helus Pharma Announces Co-Founders’ Transition from Executive Leadership as Company Advances Toward Next Stage of Development

Helus Pharma co-founders Eric So and Paul Glavine have stepped down from their executive roles (President/Executive Chairman and Chief Growth Officer, respectively) while remaining on the Board of Directors. Board member Mark Lawson, a director since November 2020, was appointed independent Chair effective immediately, and Eric So was named Chairman Emeritus. The company framed the move as a planned transition to its next stage of growth and reaffirmed it expects topline Phase 3 APPROACH data for HLP003 in major depressive disorder in Q4 2026.

•13d ago

Helus Pharma Highlights Clinical Program Advancements at Investor Presentation Held on October 21, 2026

Helus Pharma reiterated that topline data from the APPROACH Phase 3 study of HLP003 in adjunctive treatment of major depressive disorder remains on track for Q4 2026. The company also detailed its next HLP004 Phase 2 monotherapy study for generalized anxiety disorder, now expected to start in Q1 2027 with approximately 144 participants randomized 1:1 to 30 mg HLP004 or placebo. HLP003 has FDA Breakthrough Therapy Designation, and Helus expects to file an NDA in 2028; no new clinical data was disclosed in this presentation recap.

•19d ago

Helus Pharma to Host Investor Presentation on October 21, 2026

Helus Pharma will host an investor presentation on October 21, 2026 at 9:00 a.m. EDT, with a live webcast and archived replay available on its website. Discussion topics include HLP003, its Phase 3 serotonergic agonist for adjunctive treatment of major depressive disorder with FDA Breakthrough Therapy Designation, and HLP004, a Phase 2 asset for generalized anxiety disorder. This is a scheduling notice with no new clinical, financial, or corporate developments; agents should watch the October 21 event itself for substantive updates.

•1mo ago

Helus Pharma Announces Completion of Legal Name Change

Helus Pharma announced its legal name change from Cybin Inc. to Helus Pharma Inc., effective October 1, 2026, following shareholder approval on September 22. Shares continue trading on Nasdaq and Cboe Canada under the unchanged ticker HELP, with new CUSIP 423492107 and ISIN CA4234921076; shareholders need take no action. The company says the rebrand reflects its transition from clinical-stage developer toward a commercial-ready pharmaceutical company, with lead asset HLP003 in Phase 3 for adjunctive major depressive disorder under FDA Breakthrough Therapy Designation.

•1mo ago

Helus Pharma Announces Results of Annual and Special Meeting of Shareholders and Effective Date for Legal Name Change

Helus Pharma shareholders approved all proposals at the September 22, 2026 annual and special meeting, including the legal name change from Cybin Inc. to Helus Pharma Inc. with 99.3% support. The name change takes effect October 1, 2026 and follows the January 2026 adoption of the Helus Pharma business name, reflecting the company's anticipated shift toward commercial readiness. All eight director nominees were elected, though four nominees (Glavine, Halstead, Lewis-Hall, So) received roughly 28% withheld votes. Zeifmans LLP was re-appointed as auditor. Helus's pipeline remains unchanged: HLP003 in Phase 3 for adjunctive major depressive disorder with FDA Breakthrough Therapy Designation, and HLP004 in Phase 2 for generalized anxiety disorder.

•1mo ago

Helus Pharma to Participate at the TD Cowen 6th Annual Novel Mechanisms in Neuropsychiatry Summit

Helus Pharma said CEO Michael Halstead will participate in a fireside chat at the TD Cowen 6th Annual Novel Mechanisms in Neuropsychiatry Summit, a virtual event taking place September 23, 2026. The fireside chat will be webcast live at 9:00 a.m. EDT that day, with a replay available on the company's investor relations website. Helus Pharma, the commercial operating name of Cybin Inc., is a clinical-stage developer of novel serotonergic agonists; its lead asset HLP003 is in Phase 3 development for adjunctive major depressive disorder with FDA Breakthrough Therapy Designation, and HLP004 is in Phase 2 for generalized anxiety disorder. No new clinical or financial data accompanied the announcement.

•1mo ago

Helus Pharma to Participate at the Morgan Stanley 24th Annual Global Healthcare Conference in New York

Helus Pharma (Nasdaq: HELP) said Chief Executive Officer Michael Halstead will participate in a fireside chat at the Morgan Stanley 24th Annual Global Healthcare Conference in New York City. The fireside chat will be webcast live on Wednesday, September 16, 2026 at 8:30 a.m. EDT, with a replay available on the company's investor relations Events & Presentations page. Helus Pharma, the commercial operating name of Cybin Inc., is a clinical-stage developer of novel serotonergic agonists, with lead asset HLP003 in Phase 3 for adjunctive major depressive disorder under an FDA Breakthrough Therapy Designation and HLP004 in Phase 2 for generalized anxiety disorder.

•1mo ago

Helus Pharma to Participate at the H.C. Wainwright 28th Annual Global Investment Conference in New York

Helus Pharma (Nasdaq: HELP; Cboe CA: HELP) will have CEO Michael Halstead participate in a fireside chat at the H.C. Wainwright 28th Annual Global Investment Conference in New York City, September 14-16, 2026. The fireside chat webcasts live Monday, September 14, 2026 at 9:00 a.m. EDT, with a replay available on the company's investor relations Events & Presentations page. Helus Pharma, the commercial operating name of Cybin Inc., is developing HLP003 in Phase 3 for adjunctive major depressive disorder with FDA Breakthrough Therapy Designation, and HLP004 in Phase 2 for generalized anxiety disorder. No new clinical or financial data accompanies this announcement.

•2mo ago

Helus Pharma to Participate at the 2026 Cantor Global Healthcare Conference in New York

Helus Pharma (Nasdaq: HELP; Cboe CA: HELP) will participate in a fireside chat at the Cantor Global Healthcare Conference in New York City, taking place September 9-11, 2026. Chief Executive Officer Michael Halstead will represent the company; the chat webcasts live on Friday, September 11, 2026 at 8:00 a.m. EDT, with a replay available on the company's investor relations website. Helus Pharma is the commercial operating name of Cybin Inc., a clinical-stage developer of novel serotonergic agonists. Its lead asset HLP003 is in Phase 3 development for adjunctive treatment of major depressive disorder with FDA Breakthrough Therapy Designation, and HLP004 is in Phase 2 for generalized anxiety disorder.

•2mo ago

Helus Pharma to Participate at the Canaccord Genuity 46th Annual Growth Conference in Boston

Helus Pharma announced that CEO Michael Halstead will participate in a fireside chat at the Canaccord Genuity 46th Annual Growth Conference in Boston. The webcast is scheduled for Wednesday, August 12, 2026, at 12:00 p.m. EDT, with a replay available on the company's investor relations website. Helus Pharma is a clinical-stage pharmaceutical company focusing on proprietary serotonergic agonists, including HLP003 for major depressive disorder and HLP004 for anxiety.

•2mo ago

A CEO With a Proven Track Record of Success in Growing and Scaling Biopharmaceutical Companies Just Appointed CEO at a Clinical-Stage Biotech, Months Before Its Pivotal Phase 3 Readout

This article is a paid advertisement and news commentary focusing on Helus Pharma (HELP), which has appointed Michael Halstead, former President of Intra-Cellular Therapies, as its new CEO. AtaiBeckley (ATAI) is mentioned solely within a section titled "The Companies Modernizing Psychiatric Treatment" to provide sector context, cited as an example of a multi-asset platform approach alongside peers like Definium Therapeutics and Compass Pathways. No specific business developments, financial results, or corporate actions regarding AtaiBeckley are disclosed in this release.

•3mo ago

Multi-Billion-Dollar Battle for the Future of Depression Treatment Has Begun Creating a Huge Opportunity

This press release is a paid market commentary distributed by a third party on behalf of Helus Pharma; it briefly summarizes prior announcements from several biotech firms including Compass Pathways. Compass Pathways is noted for granting 157,000 stock options and 74,700 restricted share units to seventeen newly hired non-executive employees under its 2026 Inducement Plan on June 1. The awards carry an exercise price of $14.19 per share and vest over four years, representing a routine compensation event rather than new material business developments.

•4mo ago

Helus Pharma to Participate in the H.C. Wainwright 7th Annual Neuro Perspectives Conference

Helus Pharma announced that Chief Medical Officer Amir Inamdar will participate in a fireside chat at the H.C. Wainwright 7th Annual Neuro Perspectives Conference. The event takes place June 15-16, 2026, with the session available on demand starting June 15 at 7:00 a.m. EDT. This is a standard investor relations update with no new clinical or financial disclosures.

•4mo ago

Helus Pharma to Participate in the Jefferies Global Healthcare Conference in New York

Helus Pharma announced that Interim CEO Eric So will participate in a fireside chat at the Jefferies Global Healthcare Conference. The session is scheduled for Thursday, June 4, 2026, at 2:35 p.m. EDT and will be webcast live. The release includes standard boilerplate descriptions of the company’s pipeline, including HLP003 in Phase 3 for depression and HLP004 in Phase 2 for anxiety, but offers no new data or milestones.

•5mo ago

Helus Pharma to Participate at the 29th Annual Milken Institute Global Conference

Interim CEO Eric So is scheduled to speak at the 29th Annual Milken Institute Global Conference on a panel titled “The Next Wave of Health Innovation.” The conference is taking place May 3-6, 2026, in Los Angeles, with the specific panel occurring on May 4 at 2:30 p.m. PDT. Helus Pharma is currently developing HLP003, a Phase 3 treatment for major depressive disorder, and HLP004 for generalized anxiety disorder.

•6mo ago